Cadi-05(Cadi-05) - 药物靶点：TLR2_在研适应症：麻风，非小细胞肺癌_专利_临床

概要

基本信息

药物类型

治疗性疫苗

别名

Immuvac、Leprosy vaccine、Leprovac

+ [8]

靶点

TLR2

作用机制

TLR2激动剂(Toll样受体2激动剂)

治疗领域

肿瘤感染呼吸系统疾病+ [1]

在研适应症

麻风非小细胞肺癌

非在研适应症

膀胱癌新型冠状病毒感染头颈部肿瘤+ [5]

原研机构

National Institute of Immunology

在研机构

Cadila Pharmaceuticals Ltd.

National Institute of Immunology

非在研机构-

最高研发阶段批准上市

首次获批日期

印度 (1998-01-01),

麻风非小细胞肺癌

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

4

项与 Cadi-05 相关的临床试验

CTRI/2021/09/036335 / Not yet recruiting临床3期IIT

An open label assessor-blind, phase III multi-centric, randomized controlled study trial to evaluate the immunotherapeutic efficacy of Mycobacterium Indicus Pranii (MIP) vaccine, Bacillus Calmette Guerin(BCG) vaccine as an adjunct to chemotherapy in Multibacillary (MB) patients of leprosy

开始日期2021-10-18

申办/合作机构-

NCT04358809 / Unknown status临床3期

A Randomized, Double-blind, Two Arm, Controlled Clinical Trial to Compare the Efficacy and Safety of Mycobacterium w (Mw) Administered Along With Standard of Care Versus Placebo Administered Along With Standard of Care, in Adult, COVID 19 Positive Patients Hospitalized But Not Critically Ill.

This is a randomized, double blind, two arms, placebo controlled, clinical trial to study to evaluate the the safety and efficacy of Mycobacterium w in combination with standard of care versus placebo with standard of care for preventing the progression of COVID-19 disease and for reduction in transfer to ICU in COVID-19 infected patients admitted to the hospital.

开始日期2020-06-30

申办/合作机构

Cadila Pharnmaceuticals

[+1]

CTRI/2020/04/024846 / Completed临床3期

A clinical trial to evaluate the safety and efficacy of Mycobacterium W in critically ill patients suffering from COVID 19 infection

开始日期2020-04-30

申办/合作机构

Cadila Pharmaceuticals Ltd.

100 项与 Cadi-05 相关的临床结果

登录后查看更多信息

100 项与 Cadi-05 相关的转化医学

登录后查看更多信息

100 项与 Cadi-05 相关的专利（医药）

登录后查看更多信息

353

项与 Cadi-05 相关的文献（医药）

2024-10-01·Current Opinion in Neurology

Leprous neuropathy

Review

作者: Marques, Wilson

Purpose of reviewLeprosy is still an important cause of neuropathy. Late diagnosis is associated with development of severe nerve impairment.Recent findingsearly diagnosis and early treatment is essential in order to avoid disability and disease transmission. Recognizing that leprosy is a neurological disease is a fundamental step to the Leprosy zero action proposed by the World Health OrganizationSummaryleprosy neuropathy manifests as a mononeuropathy or a multiple mononeuropathy with a temperature-dependent distribution. Electromyography, high-resolution sonography serology and PCR help make the diagnosis. Multidrug therapy should be instituted.

2024-10-01·International Journal of Dermatology

Leprosy knowledge among primary care physicians in Southern Brazil: are we underdiagnosing?

Article

作者: de Cássia Francisco, Priscila ; Kliemann, Breno Saty ; Tarlé, Roberto Gomes

AbstractBackgroundLeprosy is a chronic infection with high morbidity in Brazil. Primary care physicians' lack of knowledge about the disease may play a significant role in underdiagnosis. This study aimed to assess primary care physicians' ability to identify typical leprosy skin lesions and their knowledge of the subject.MethodsThis cross‐sectional study relied on a questionnaire in which participating doctors chose one main diagnostic hypothesis and two differential diagnoses for each skin lesion presented. Five leprosy lesions were included. Questions regarding management, follow‐up, and diagnostic workup for the disease were also included. The questionnaire was sent to primary care physicians working in Curitiba, in the Southern Brazilian state of Paraná, and dermatologists, who constituted the control group.ResultsThirty‐two primary care physicians and 26 dermatologists agreed to participate in the study. Primary care physicians accurately identified a mean of 1.8 ± 1.2 of the five leprosy skin lesions, while dermatologists accurately identified 2.5 ± 0.9 (P = 0.009). The main misdiagnosed leprosy forms were the lepromatous and histoid variants. Among primary care physicians, 56.2% claimed to have little knowledge of the subject and a large share of participants was unaware of recent updates in treating paucibacillary forms, even within the dermatologist subgroup.ConclusionsPrimary care physicians in Curitiba have little information regarding the diagnosis, treatment, and follow‐up of leprosy. Even dermatologists had difficulties with treatment and patient management, emphasizing the constant need for education on this subject.

2024-09-01·Microvascular Research

Nail fold capillaroscopy in leprosy: Unveiling the microvascular changes

Article

作者: Gandhi, Vijay ; Aggarwal, Amitesh ; Aggarwal, Bharti ; Singal, Archana ; Saha, Sushobhan

BACKGROUNDLeprosy, a chronic infectious disease, is associated with various nail changes. Its etiopathogenesis is multifaceted, with microvascular damage being crucial. Nail fold capillaroscopy (NFC) emerges as a novel tool for detecting early vascular deficits in leprosy. The study aimed to assess and provide a complete clinical characterization of NFC changes in leprosy patients.METHODSIt is an observational cross-sectional study, done over a period of 1.5 year (January 2021 to august 2022) in a tertiary care hospital, encompassing 60 patients diagnosed with leprosy (18-60 years). After obtaining informed consent; detailed history, complete cutaneous and neurological examinations were conducted. All fingernails and toenails were examined for clinical changes. Subsequently, onychoscopy was performed using USB type of video-dermatoscope (Model AM7115MZT Dino-lite), a non-invasive tool. This was followed by NFC which was done for all fingernails and images were recorded by single operator, which were then assessed for quantitative and qualitive changes and statistical analysis was conducted using SPSS v20, with mean capillary density compared using Student's t-test, morphological change frequencies assessed by proportions, and group comparisons made using Chi-square or Fischer exact tests, with a significance threshold of p < 0.05.RESULTSAmong the 60 patients, 39 were in the lepromatous group, which included both borderline lepromatous (BL) and lepromatous leprosy (LL) patients, and 17 were in the tuberculoid group, which included borderline tuberculoid (BT) leprosy patients; 23.3 % had Type 1 reactions, and 18.3 % had Type 2 reactions. Nail fold capillaroscopy (NFC) showed microvasculature changes in 93.3 % of patients. The average capillary density was 6.8 ± 1.5 capillaries per mm, with the lepromatous group having a lower density (6.5 ± 1.09) compared to the tuberculoid group (7.0 ± 0.86). The most common NFC changes in the tuberculoid group were tortuous capillaries (70 %), capillary dropouts, and dilated capillaries (both 64.7 %). In the lepromatous group, capillary dropouts (82 %) were most frequent, followed by tortuous (69 %), receding (69 %), and dilated capillaries (66 %). A dilated and prominent subpapillary plexus was more common in the lepromatous group (35 %, p = 0.04). Patients with trophic changes in the lepromatous group had more capillary dropouts and bizarre capillaries. Capillary dropouts, dilated capillaries, and visible subpapillary venous plexus were more prevalent in patients with Type 2 reactions.CONCLUSIONNFC changes are prevalent in both tuberculoid and lepromatous leprosy, which may be an indicator of peripheral vascular compromise and trophic changes, especially in lepromatous leprosy. NFC can be an auxiliary tool for detecting microvascular abnormalities in leprosy patients.

100 项与 Cadi-05 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	J07AX	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
麻风	印度	-	1998-01-01
非小细胞肺癌	印度	-	1998-01-01

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
黑色素瘤	临床1期	美国	Cadila Pharmaceuticals Ltd.	-
前列腺癌	临床1期	印度	Cadila Pharmaceuticals Ltd.	-
新型冠状病毒感染	临床前	印度	Cadila Pharmaceuticals Ltd.	2020-05-14
结核	临床前	印度	Cadila Pharmaceuticals Ltd.	2018-07-17
脓毒症	临床前	印度	Cadila Pharmaceuticals Ltd.	2015-05-23
膀胱癌	临床前	印度	Cadila Pharmaceuticals Ltd.	-
头颈部肿瘤	临床前	印度	Cadila Pharmaceuticals Ltd.	-
多发性骨髓瘤	临床前	印度	Cadila Pharmaceuticals Ltd.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


Literature 人工标引	临床1期	星形细胞瘤 \| 胶质母细胞瘤 \| 睾丸肿瘤 \| 支气管癌 \| 膀胱癌 \| 纤维肉瘤 \| 头颈部肿瘤	24	Cadi-05	醖簾餘構糧膚繭簾齋網(醖糧鹹齋鏇餘簾齋餘餘) = 蓋簾窪窪壓憲願構繭觸選衊窪鬱鬱鏇積餘膚範 (壓窪餘衊壓夢製蓋齋餘 )	积极	2008-05-20